Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Carfilzomib Cardiovascular Disease: Use of the Atherosclerotic Cardiovascular Disease Score to Predict Cardiovascular Events in Multiple Myeloma Patients Treated with Carfilzomib

Ricardo Parrondo, MD, Tracy Andrews, MSc, Rima M Panchal, MD, Sejal Kothadia, MD, Camille Johnson, MD, Jieqi Liu, Giselle Alexandra Suero-Abreu, MD PhD, David H. Vesole, MD PhD, David S Siegel, MD PhD, Noa Biran, MD

Blood (2018) 132 (Supplement 1): 3254.

https://doi.org/10.1182/blood-2018-99-113722

Published: 2018

Journal Articles

Ten-Day Decitabine Treatment in AML Associated with Reversible Non-Ischemic Cardiomyopathy

Bhavisha Patel, MD, Barac Ana, MD, Kelly W. Fitzpatrick, MD, Aarthi Shenoy, MD

Blood (2017) 130 (Supplement 1): 5032.

https://doi.org/10.1182/blood.V130.Suppl_1.5032.5032

Published: 2017

Journal Articles

Beta-Blockers Improved Survival Outcomes in Patients with Multiple Myeloma: A Retrospective Evaluation

Yi L. Hwa, DNP, Qian Shi, PhD, Shaji Kumar, MD, Martha Q. Lacy, MD, Morie A. Gertz, MD MACP, Prashant Kapoor, MD, Francis K Buadi, MD, Nelson Leung, MD, David Dingli, MD PhD, Ronald S. Go, MD, Suzanne R. Hayman, MD, Wilson I Gonsalves, MD, Stephen J. Russell, MD PhD, John A Lust, MD PhD, Yi Lin, MD PhD, S. Vincent Rajkumar, MD, Angela Dispenzieri, MD

Blood (2016) 128 (22): 3306.

https://doi.org/10.1182/blood.V128.22.3306.3306

Published: 2016

Journal Articles

A Multicenter Phase II Study Of Bortezomib (VELCADE®) Combined With Rituximab For Untreated High Tumor Burden (HTB) Indolent Non-Hodgkin Lymphoma (NHL): Long-Term Follow-Up Of Outcomes and Examination Of Prognostic Factors

Andrew M Evens, DO, MSc, Mitchell R Smith, MD, PhD, Izidore S Lossos, MD, Irene Helenowski, PhD, Michael Millenson, MD, Jane N. Winter, MD, Steven T. Rosen, MD, FRCPA, Leo I. Gordon, MD

Blood (2013) 122 (21): 1807.

https://doi.org/10.1182/blood.V122.21.1807.1807

Published: 2013

Journal Articles

Cardiac and Pulmonary Safety Profile of Single-Agent Carfilzomib From Four Phase 2 Studies in Patients with Relapsed and/or Refractory Multiple Myeloma

Sagar Lonial, MD, Ruben Niesvizky, MD, Leanne McCulloch, PharmD, Kanya Rajangam, MD, PhD, Ravi Vij, MD

Blood (2012) 120 (21): 4037.

https://doi.org/10.1182/blood.V120.21.4037.4037

Published: 2012

Journal Articles

Repeated Doses of Adriamycin May Be Safely Delivered through the Intraosseous Route In Different Bones In Swine

Rodrigo Lima, MD, MS, Lais Navarro, PhD, Fernando Cesani, MD, Hal K. Hawkins, MD, Frederick Huang, MD, PhD, Daneshvari R. Solanki, MD, Thomas Philbeck, PhD, Larry Miller, MD

Blood (2010) 116 (21): 4344.

https://doi.org/10.1182/blood.V116.21.4344.4344

Published: 2010

Journal Articles

Response Rate of 16% and High Incidence of Adverse Events In Placebo-Treated Patients with CD25 Assay-Positive Cutaneous T-Cell Lymphoma (CTCL): An Analysis of Patient Characteristics and Predictors of Response

Miles Prince, MD, FRACP, FRCPA, Madeleine Duvic, MD, Ann Martin, MD, Wolfram Sterry, MD, Chalid Assaf, MD, David Straus, MD

Blood (2010) 116 (21): 4158.

https://doi.org/10.1182/blood.V116.21.4158.4158

Published: 2010

Journal Articles

Health Outcomes in Childhood Cancer Survivors: Screening for Anthracycline-Induced Cardiac Toxicity.

Jeffrey R. Andolina, MD, Kimberley Dilley, MD, MPH

Blood (2009) 114 (22): 70.

https://doi.org/10.1182/blood.V114.22.70.70

Published: 2009

Journal Articles

Prevelance of Cardiac Dysfunction in Patients with Thalassemia Major with Respect to Cardiac Magnetic Resonance.

Antonios Kattamis, Vasilios Berdoukas, MB, BS, Eleni Berdoussi, Kirikos Zannikos, Vassilios Ladis

Blood (2009) 114 (22): 2013.

https://doi.org/10.1182/blood.V114.22.2013.2013

Published: 2009

Journal Articles

Total Marrow Irradiation (TMI): A New Ablative Regimen as Part of Tandem (T) Autologous Peripheral Blood Progenitor Cell Transplant (AT) for Patients (pts) with Multiple Myeloma (MM).

George Somlo, M.D., F.A.C.P., Ricardo Spielberger, MD, Paul Frankel, Chatchada Karanes, MD, Amrita Krishnan, MD, FACP, Pablo Miguel Parker, MD, Leslie Popplewell, Firoozeh Sahebi, Tim Schultheiss, Neil Martin Kogut, MD, An Liu, David S. Snyder, MD, Stephen J. Forman, Jeffrey Y. Wong

Blood (2008) 112 (11): 3326.

https://doi.org/10.1182/blood.V112.11.3326.3326

Published: 2008

Journal Articles

Lenalidomide, Bortezomib, and Dexamethasone (Rev/Vel/Dex) in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Preliminary Results of a Phase II Study.

Blood (2007) 110 (11): 2714.

https://doi.org/10.1182/blood.V110.11.2714.2714

Published: 2007

Journal Articles

Cardiovascular Involvement in Thalassemia Major Patients: WEB-THAL® Data Analysis (A Web-Based Multicentric Database).

Giorgio Derchi, MD, Francesco Formisano, MD, Martina Lamagna, MD, Renzo Galanello, MD, Patrizio Bina, MD, Maria Domenica Cappellini, MD, Maria Rosaria Fasulo, MD, Antonio Piga, MD, Guido Donato, MD, Gianni Quarta, MD, Angela Melpignano, MD, Carla Tazzer, Gian Luca Forni, MD

Blood (2007) 110 (11): 3824.

https://doi.org/10.1182/blood.V110.11.3824.3824

Published: 2007

Journal Articles

Left Ventricular Cardiac Function during the Course of a One Year Multicenter Trial of the Safety and Efficacy with ICL670 5–40mg/kg/day and Deferoxamine 20–60 mg/kg/day in Beta-Thalassemia Patients with Transfusional Hemosideosis.

Dorothy A. Kleinert, NP, MPH, Erica Jones, MD, Cristina P. Sison, PhD, Peter Marks, MD, PhD, Patricia J. Giardina, MD

Blood (2005) 106 (11): 3853.

https://doi.org/10.1182/blood.V106.11.3853.3853

Published: 2005

Journal Articles

Arsenic Trioxide (As 2 O 3 ) in the Treatment of Patients with Newly Diagnosed Acute Promyelocytic Leukemia (APML) - Toxicity and Outcome.

Biju George, MD, DM, Vikram Mathews, MD, DM, Auro Vishwabandhya, MD, DM, Alok Srivastava, MD, FRCPA, Mammen Chandy, MD, FRCPA

Blood (2004) 104 (11): 889.

https://doi.org/10.1182/blood.V104.11.889.889

Published: 2004

NARROW

Carfilzomib Cardiovascular Disease: Use of the Atherosclerotic Cardiovascular Disease Score to Predict Cardiovascular Events in Multiple Myeloma Patients Treated with Carfilzomib

Ten-Day Decitabine Treatment in AML Associated with Reversible Non-Ischemic Cardiomyopathy

Beta-Blockers Improved Survival Outcomes in Patients with Multiple Myeloma: A Retrospective Evaluation

A Multicenter Phase II Study Of Bortezomib (VELCADE®) Combined With Rituximab For Untreated High Tumor Burden (HTB) Indolent Non-Hodgkin Lymphoma (NHL): Long-Term Follow-Up Of Outcomes and Examination Of Prognostic Factors

Cardiac and Pulmonary Safety Profile of Single-Agent Carfilzomib From Four Phase 2 Studies in Patients with Relapsed and/or Refractory Multiple Myeloma

Repeated Doses of Adriamycin May Be Safely Delivered through the Intraosseous Route In Different Bones In Swine

Response Rate of 16% and High Incidence of Adverse Events In Placebo-Treated Patients with CD25 Assay-Positive Cutaneous T-Cell Lymphoma (CTCL): An Analysis of Patient Characteristics and Predictors of Response

Health Outcomes in Childhood Cancer Survivors: Screening for Anthracycline-Induced Cardiac Toxicity.

Prevelance of Cardiac Dysfunction in Patients with Thalassemia Major with Respect to Cardiac Magnetic Resonance.

Total Marrow Irradiation (TMI): A New Ablative Regimen as Part of Tandem (T) Autologous Peripheral Blood Progenitor Cell Transplant (AT) for Patients (pts) with Multiple Myeloma (MM).

Lenalidomide, Bortezomib, and Dexamethasone (Rev/Vel/Dex) in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Preliminary Results of a Phase II Study.

Cardiovascular Involvement in Thalassemia Major Patients: WEB-THAL® Data Analysis (A Web-Based Multicentric Database).

Left Ventricular Cardiac Function during the Course of a One Year Multicenter Trial of the Safety and Efficacy with ICL670 5–40mg/kg/day and Deferoxamine 20–60 mg/kg/day in Beta-Thalassemia Patients with Transfusional Hemosideosis.

Arsenic Trioxide (As 2 O 3 ) in the Treatment of Patients with Newly Diagnosed Acute Promyelocytic Leukemia (APML) - Toxicity and Outcome.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only